REGENXBIO

$39.21
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.93 (-2.32%) Today
$0.00 (0.00%) As of 9:20 PM UTC after-hours

Why Robinhood?

You can buy or sell REGENXBIO and other stocks, options, and ETFs commission-free!

About RGNX

REGENXBIO Inc. Common Stock, also called REGENXBIO, is a biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. The company was founded by Kennth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD. The listed name for RGNX is REGENXBIO Inc. Common Stock.

CEO
Kenneth T. Mills
Employees
257
Headquarters
Rockville, Maryland
Founded
2008
Market Cap
1.62B
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
432.72K
High Today
$40.61
Low Today
$38.35
Open Price
$39.75
Volume
418.57K
52 Week High
$50.26
52 Week Low
$20.03

RGNX News

BenzingaMar 1

Recap: Regenxbio Q4 Earnings

Shares of Regenxbio (NASDAQ:RGNX) fell in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share fell 72.22% over th

RGNX Earnings

-$1.24
-$0.75
-$0.26
$0.23
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
-$0.43 per share
Actual
-$1.24 per share
Replay Earnings Call

You May Also Like

CBB
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure